Parkinson's disease drug research is increasingly targeting brain inflammation, moving beyond the traditional focus on alpha-synuclein protein. Despite past failures in alpha-synuclein therapies, new approaches aim to address multiple disease mechanisms, including neuroinflammation, which may interact with protein buildup. Companies like Ventyx Biosciences and BioVie are developing drugs that reduce brain inflammation, showing promising early trial results. Analysts see this shift as a pivotal moment for Parkinson's treatments, with a potential market worth $8 billion by 2035.
Truist Financial raised its price target for RXO to $28, signaling a 30% potential gain after the company reported strong Q2 results. RXO posted $1.77 billion in revenue, a 25% increase year-over-year, surpassing analyst estimates by nearly 15%. Earn...
Under Armour reported Q1 earnings with an EPS of $0.05, beating analyst estimates of $0.02 by 150%. However, revenue fell 3% year-over-year to $1.1 billion, slightly below expectations, mainly due to a 9% decline in North American sales. Internationa...
National Energy Services Reunited Corp. (NESR) is set to release its Q2 2026 earnings on August 10, with analysts expecting earnings per share of $0.35 and revenue of $448.54 million. The company recently secured $300 million in new five-year contrac...
Truist Financial raised Parker-Hannifin's price target to $1,358, reflecting a potential 25.78% upside after the company reported strong Q4 FY2026 adjusted earnings of $9.27 per share, beating estimates and showing 21% growth year-over-year. Sales hi...
RBC Capital increased its price target for RioCan to C$25.00 and maintained an "Outperform" rating, reflecting confidence in the REIT's strong operational performance. RioCan reported a high retail occupancy rate of 98.80% and a 6.10% rise in net inc...
